HC Wainwright Has Optimistic Outlook of TARS Q3 Earnings

Key Points

• HC Wainwright raised its Q3 EPS forecast for Tarsus Pharmaceuticals from ($0.35) to ($0.32), maintaining a "Buy" rating with a price target of $72.00.
• Tarsus Pharmaceuticals reported a Q2 earnings miss with EPS at ($0.48), below the consensus estimate of ($0.33), although revenue of $102.66 million exceeded expectations.
• Institutional investors own approximately 90.01% of Tarsus Pharmaceuticals' stock, indicating strong institutional backing.

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) - Research analysts at HC Wainwright upped their Q3 2025 EPS estimates for Tarsus Pharmaceuticals in a research report issued on Thursday, August 7th. HC Wainwright analyst M. Caufield now forecasts that the company will post earnings per share of ($0.32) for the quarter, up from their prior forecast of ($0.35). HC Wainwright currently has a "Buy" rating and a $72.00 target price on the stock. The consensus estimate for Tarsus Pharmaceuticals' current full-year earnings is ($3.17) per share. HC Wainwright also issued estimates for Tarsus Pharmaceuticals' Q4 2025 earnings at ($0.14) EPS, FY2025 earnings at ($1.56) EPS, FY2026 earnings at ($2.15) EPS and FY2028 earnings at $0.30 EPS.

A number of other analysts also recently issued reports on the stock. Oppenheimer assumed coverage on shares of Tarsus Pharmaceuticals in a report on Monday, June 2nd. They issued an "outperform" rating and a $75.00 price objective on the stock. Wall Street Zen cut shares of Tarsus Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, May 22nd. The Goldman Sachs Group raised their target price on shares of Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the company a "neutral" rating in a research note on Monday, May 5th. Finally, Guggenheim raised their target price on shares of Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. Two analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $66.67.

Tarsus Pharmaceuticals Stock Down 0.5%

Shares of NASDAQ TARS traded down $0.28 during midday trading on Monday, reaching $52.44. The company's stock had a trading volume of 106,919 shares, compared to its average volume of 659,439. The company has a current ratio of 5.26, a quick ratio of 5.21 and a debt-to-equity ratio of 0.22. Tarsus Pharmaceuticals has a fifty-two week low of $24.95 and a fifty-two week high of $57.28. The stock has a market capitalization of $2.21 billion, a price-to-earnings ratio of -22.58 and a beta of 0.79. The stock has a 50 day simple moving average of $42.02 and a 200-day simple moving average of $45.76.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.15). Tarsus Pharmaceuticals had a negative net margin of 31.13% and a negative return on equity of 32.36%. The business had revenue of $102.66 million during the quarter, compared to analyst estimates of $95.81 million.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

Institutional investors have recently modified their holdings of the business. GF Fund Management CO. LTD. bought a new stake in shares of Tarsus Pharmaceuticals in the fourth quarter valued at about $44,000. Amalgamated Bank lifted its position in Tarsus Pharmaceuticals by 30.1% during the first quarter. Amalgamated Bank now owns 1,274 shares of the company's stock worth $65,000 after purchasing an additional 295 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its position in Tarsus Pharmaceuticals by 26.4% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,623 shares of the company's stock worth $66,000 after purchasing an additional 339 shares during the period. Quarry LP bought a new stake in Tarsus Pharmaceuticals during the fourth quarter worth about $166,000. Finally, AlphaQuest LLC bought a new stake in Tarsus Pharmaceuticals during the first quarter worth about $189,000. Institutional investors own 90.01% of the company's stock.

Insider Buying and Selling

In other news, CEO Bobak R. Azamian sold 6,000 shares of the business's stock in a transaction dated Monday, August 11th. The shares were sold at an average price of $50.00, for a total value of $300,000.00. Following the completion of the sale, the chief executive officer owned 818,106 shares of the company's stock, valued at approximately $40,905,300. The trade was a 0.73% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 8.97% of the stock is currently owned by company insiders.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.